Ivermectin-Based Mass Drug Administration for Scabies in Northern India: A Single-Arm Community Intervention Trial
Authors
Daniel Engelman
Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Andrew Steer
Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Molly Thomas
Department of Dermatology, Herbertpur Christian Hospital, Dehradun, Uttarakhand, India
Anneke Grobler
Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
Xilin Zhu
Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Raj Singh
Garhwal Community Development and Welfare Society, Chamba, Uttarakhand, India
Howard O’Brien
Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Hannah Woodall
Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Rajesh Singh
Garhwal Community Development and Welfare Society, Chamba, Uttarakhand, India
Nathan Grills
Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Keywords:
dermatology, ivermectin, mass drug administration, neglected tropical diseases, scabies
Abstract
Scabies and impetigo cause direct health effects and contribute to severe infectious and immune-mediated complications. Ivermectin-based mass drug administration can reduce scabies and impetigo prevalence in island settings with high prevalence, but the effectiveness in moderate-prevalence settings is not known.
Methods
We conducted a single-arm, before–after community intervention trial. Mass drug administration was offered to the entire population of 4 villages in Uttarakhand, India. The treatment consisted of 2 doses, given 7 days apart, of oral ivermectin (∼200 μg/kg), or topical 5% permethrin if ivermectin was contraindicated. The primary outcome was the prevalence of scabies at 12 months compared with baseline, as diagnosed using clinical assessment and the 2020 International Alliance for the Control of Scabies criteria. Secondary outcomes included the prevalence of impetigo at each time point. The trial was registered with the Australian and New Zealand Trials Registry (ACTRN12619001712190).
Results
In January 2020, 1211 participants were enrolled (100% of the estimated village population). Treatment coverage was high—1204 (99.4%) and 1177 (97.2%) received 1 and 2 doses, respectively. Scabies was diagnosed in 91 participants (7.5%) and impetigo in 15 (1.2%). In February 2021, 1190 (98.3% of baseline) participants re-enrolled, and of these 11 had scabies (0.9%; relative risk reduction, 87.7%; 95% CI, 77.1%–93.4%) and 5 had impetigo (0.4%; relative risk reduction, 66.1%; 95% CI, 7.0%–87.6%).
Conclusions
A single round of ivermectin-based mass drug administration substantially reduced the prevalence of scabies and impetigo in this setting with moderate scabies prevalence in northern India.
Keywords: dermatology, ivermectin, mass drug administration, neglected tropical diseases, scabies
Author Biographies
Daniel Engelman, Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Melbourne Children's Global Health, Royal Children's Hospital, Melbourne, Victoria, Australia
Andrew Steer, Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Melbourne Children's Global Health, Royal Children's Hospital, Melbourne, Victoria, Australia
Anneke Grobler, Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
Clinical Epidemiology & Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Howard O’Brien, Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Nathan Grills, Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
Australia India Institute, University of Melbourne, Melbourne, Victoria, Australia
Click on "Archives" to access the full archive of scientific preprints. You may use the categories and the search functionality to find select preprints you're interested in.